Ranitidine reduces phosphate binding in dialysis patients receiving calcium carbonate.
Nephrol Dial Transplant
; 11(5): 851-3, 1996 May.
Article
em En
| MEDLINE
| ID: mdl-8671908
ABSTRACT
BACKGROUND:
In a previous controlled study we showed that ranitidine significantly reduced the phosphate binding of aluminium hydroxide in patients with renal failure, probably increasing intragastric pH.METHODS:
In this study we have investigated the effect of ranitidine on the phosphate binding of calcium carbonate in fifteen dialysis patients. Ranitidine 300 mg or a placebo tablet was taken before breakfast for two 4-week periods in a double-blind crossover trial with no washout period. The mean daily dose of calcium carbonate was 2 g and neither the dose nor the patient's diet was changed during the study period. Blood was taken at 2-weekly intervals for serum phosphate, calcium, albumin, and alkaline phosphatase measurements, and at the end of each treatment period for parathyroid hormone (PTH) level.RESULTS:
Serum phosphate concentrations were significantly higher during the ranitidine than the placebo phase, 1. 78 (+/-0.43 SD) versus 1.59 (+/-0.49 SD) mmol/l (P<0.001). Serum calcium, albumin, PTH, and alkaline phosphatase concentrations did not differ between the two treatment periods.CONCLUSION:
This study shows that ranitidine has a significant adverse effect on the phosphate binding of calcium carbonate in patients with renal failure.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Fosfatos
/
Ranitidina
/
Carbonato de Cálcio
/
Antagonistas dos Receptores H2 da Histamina
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Nephrol Dial Transplant
Assunto da revista:
NEFROLOGIA
/
TRANSPLANTE
Ano de publicação:
1996
Tipo de documento:
Article
País de afiliação:
Reino Unido